# Junta clínica — PT-pseudo_21e7fa67a79e (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_21e7fa67a79e",
  "pid": "PT-pseudo_21e7fa67a79e",
  "task": 1,
  "psa": 11.0,
  "age": 70,
  "months": 3,
  "pirads": "5",
  "psad": 0.108,
  "psav": 2.49,
  "psap": 7.8,
  "vol": 101.95,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.77544403,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 11 ng/mL. PI-RADS 5. PSAD 0.11. Prostate volume 102 mL. csPCa 0.78.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "100 kg",
    "height": "183 cm",
    "bmi": "29.9",
    "bp": "123/79 mmHg",
    "hr": "72 bpm",
    "smoking": "Ex-smoker (29 pack-yr, quit 2007)",
    "last_dental": "6 mo ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "01 Feb 2025",
  "enc_ref": "Dr. N. Kuiper (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Assessment of a previously positive prostate biopsy alongside a steadily climbing PSA trajectory."
    },
    {
      "s": "History",
      "t": "First brought to clinical attention for a PSA elevation in late 2022, this 70-year-old gentleman has a previously positive prostate biopsy bucket recording Gleason 3+4 pathology. He endures severe lower urinary tract symptoms, scoring 34 on the IPSS, which heavily disrupts his daily activities despite a lack of prior surgical interventions. A retired postal worker who has never married, he resides alone with his adult daughter acting as primary contact and a longstanding friend listed as next of kin. His lifestyle includes cycling roughly 20 kilometres twice each week and drinking about five alcohol units weekly; he ceased smoking 29 pack-years ago back in 2007. Aside from a right knee arthroscopy in 2018 and a recent practice-nurse-administered influenza vaccine, his medical background remains clear. He explicitly denies unexplained weight loss, bone pain, or haematuria."
    },
    {
      "s": "Physical examination",
      "t": "Normal DRE: The prostate measures symmetrically enlarged, presenting a smooth capsule devoid of palpable nodules or asymmetry. General examination remains unremarkable, characterised by stable vital signs and an absence of systemic illness or lymphadenopathy."
    }
  ],
  "occupation": "retired postal worker",
  "marital": "Never married",
  "living": "Lives alone; adult daughter is primary contact",
  "next_of_kin": "Long-time friend (no close family)",
  "recent_other": [
    "GP practice nurse — flu vaccination"
  ],
  "alcohol": "5 units / week",
  "exercise": "Cycling 2x/week, ~20 km",
  "ipss": "IPSS score: 34/35 (severe LUTS)",
  "admin": "Interpreter: not required. Consent for data use: signed.",
  "mri_hospital": "LUMC (Leiden)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_21e7fa67a79e
Task: 1

Encounter: Urology - outpatient on 01 Feb 2025.
Referrer: Dr. N. Kuiper (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 70-year-old male
  - PSA: 11.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.108 ng/mL²
  - PSA velocity: 2.49 ng/mL/yr
  - Prior PSA: 7.8 ng/mL
  - Prostate volume: 101.95 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.77544403 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 11 ng/mL. PI-RADS 5. PSAD 0.11. Prostate volume 102 mL. csPCa 0.78.

Vitals: weight 100 kg, height 183 cm, BMI 29.9, BP 123/79 mmHg, HR 72 bpm. Smoking: Ex-smoker (29 pack-yr, quit 2007).

Chief complaint: Assessment of a previously positive prostate biopsy alongside a steadily climbing PSA trajectory.

History: First brought to clinical attention for a PSA elevation in late 2022, this 70-year-old gentleman has a previously positive prostate biopsy bucket recording Gleason 3+4 pathology. He endures severe lower urinary tract symptoms, scoring 34 on the IPSS, which heavily disrupts his daily activities despite a lack of prior surgical interventions. A retired postal worker who has never married, he resides alone with his adult daughter acting as primary contact and a longstanding friend listed as next of kin. His lifestyle includes cycling roughly 20 kilometres twice each week and drinking about five alcohol units weekly; he ceased smoking 29 pack-years ago back in 2007. Aside from a right knee arthroscopy in 2018 and a recent practice-nurse-administered influenza vaccine, his medical background remains clear. He explicitly denies unexplained weight loss, bone pain, or haematuria.

Physical examination: Normal DRE: The prostate measures symmetrically enlarged, presenting a smooth capsule devoid of palpable nodules or asymmetry. General examination remains unremarkable, characterised by stable vital signs and an absence of systemic illness or lymphadenopathy.

Patient info: retired postal worker; Never married; Lives alone; adult daughter is primary contact.
Next of kin: Long-time friend (no close family).

Lifestyle: alcohol 5 units / week; exercise Cycling 2x/week, ~20 km; IPSS score: 34/35 (severe LUTS).

Recent other appointments: GP practice nurse — flu vaccination.
Admin: Interpreter: not required. Consent for data use: signed.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.62
  uncertainty  +/- 0.12 epistemic (95% band 0.39-0.84); among patients I cannot tell apart the outcome was 0.96 of 1.00 mixed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 48 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.12: PI-RADS 5, PSA 5.5, PSAD 0.12, age 71, DRE Normal -> BIOPSY (clear). He wrote: "Prev biopsy finding is left lobe, MRI finding highly suspicious of ISUP≥2 on right side. Active surveillance, only 1 biopsy session performed (of unclear date and unclea…"
  2. distance 1.53: PI-RADS 5, PSA 10.0, PSAD 0.27, age 75, DRE Normal -> BIOPSY (clear). He wrote: "New(? -> no old MRI report included) PIRADS 5 and rising PSA makes biopsy necessary"
  3. distance 1.78: PI-RADS 5, PSA 19.0, PSAD 0.37, age 65, DRE Normal -> DEFER (clear). He wrote: "Patient needs treatment without repeat biopsy as earlier biopsy showed ISUP4"

PRECEDENT: BIOPSY (weighted vote 0.73 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 48 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline addresses the need for repeat biopsy when there is a lesion on MRI, and the role of repeat PSA testing. "sion on MRI mandates a repeat biopsy to confirm histological progression before a change in treatment strategy." It also notes that a stable MRI (PRECISE 1-3) with a low PSA-D (< 0.15) may lead to omitting a repeat biopsy.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert-STRUCTURED's suggestion of biopsy is not settled because the guideline makes the decision dependent on the MRI findings and PSA density, which are not fully resolved by the panel variables alone. The precedent cited by Expert-LIBRARY shows that the decision to biopsy varied based on the specific PI-RADS score and PSA level, which is a fact the guideline makes decisive that no panel variable represents.

WHAT WE STILL NEED
The panel already contains the following known facts:
*   **Prior biopsy status:** Positive. This is crucial as the guideline discusses repeat biopsy after a prior positive biopsy.
*   **PI-RADS:** 5. This is a high-risk finding that the guideline links to the need for further investigation.
*   **PSA:** 11.0 ng/mL. This value is above the threshold mentioned in the search results for PSA testing.
*   **PSA density:** 0.108 ng/mL². This value is relevant as the guideline mentions PSA density in relation to omitting repeat biopsy.
*   **Months since last PSA:** 3. This is relevant for assessing the PSA trend.
*   **csPCa probability:** 0.77544403. This probability is a clinical measure that the guideline does not directly use as a decision point.
*   The documented grade of the prior biopsy (Gleason or ISUP) is not explicitly stated in the panel, which is a factor the guideline makes decisive.
*   The mpMRI prose is not available to assess the PRECISE score, which is a factor the guideline makes decisive.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on determining the grade of the prior biopsy and the specific MRI characteristics to determine if a repeat biopsy is mandated by the EAU guidelines.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size, zone, extraprostatic extension, and comparison against earlier studies?
  psa_trend (get_psa_trend) -> What is the trend of the serial PSA values?
  previous_notes (get_previous_notes) -> What is the documented grade (Gleason or ISUP) of the prior biopsy, the number and dates of biopsy sessions, and surveillance protocol status?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented grade (Gleason or ISUP) of the prior prostate biopsy?
  Q2. What are the specific characteristics of the mpMRI prose, such as the PRECISE score, to assess the need for a repeat biopsy according to EAU guidelines?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The lesion size is approximately "28 mm in maximum dimension" in the "left peripheral zone at the base/mid-gland level". The comparison against earlier studies is "new" as it is a new MRI report.
psa_trend
The trend of the serial PSA values is: {"date": "Dec 2022", "val": 10.2}, {"date": "Aug 2023", "val": 9.2}, {"date": "May 2024", "val": 5.2}, {"date": "Feb 2025", "val": 11.0}.
previous_notes
The documented grade of the prior biopsy is "Gleason 3+4 pathology". There has been "1" biopsy session recorded, with the date being "not recorded", and the surveillance protocol status is "not recorded".

WHAT I DID NOT OPEN
I did not open the laboratory results or the family-history anamnesis because the previous notes provided the necessary information regarding the prior biopsy grade and surveillance status, and the laboratory results were not explicitly required by the moderator's questions.

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now:
PI-RADS 5 lesion in the left peripheral zone.
Rising PSA trend from 5.2 ng/mL in May 2024 to 11.0 ng/mL in Feb 2025.
Prior biopsy finding of Gleason 3+4 pathology.

Findings that argue AGAINST sampling this patient now:
Prior biopsy finding of Gleason 3+4 pathology.
Surveillance protocol status is "not recorded".

WHERE THIS LEANS
The combination of a PI-RADS 5 finding and a rising PSA trend strongly supports the need for further investigation, aligning with the EAU guideline's emphasis on repeat biopsy when MRI findings are high-risk.
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 11.00 ng/mL over 4 points spanning 26 months; velocity -0.19 ng/mL per year; no meaningful doubling time.
PROJECTION at 6 months: 24.0 ng/mL, conformal 95% band 6.9-83.7.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.58
  uncertainty  +/- 0.11 epistemic (95% band 0.36-0.80), of which 0.00 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 59% of the time over the 29 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.62  ('supports' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.58  ('discuss' tier, fusion_nolab)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=0.73  (k=3 precedents)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.62 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-STRUCTURED carried the most weight ('supports' tier). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened—radiology_report, psa_trend, and previous_notes—address the moderator's questions to some extent. The registrar retrieved the Gleason 3+4 pathology from previous_notes, which answers Q1. However, the specific mpMRI prose characteristics, such as the PRECISE score, required by Q2, were not explicitly retrieved or reported in the retrieved documents.

ALIGNMENT WITH THE PANEL
The panel protocol concluded BIOPSY based on a weighted vote, noting that the documented prior grade was "none recorded" in the opened documents. The registrar did retrieve the Gleason 3+4 finding, which is a critical piece of information that was not explicitly factored into the panel's final decision-making process as stated.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented grade (Gleason or ISUP) of the prior prostate biopsy? This was answered by the registrar, who reported "Gleason 3+4 pathology".
Q2. What are the specific characteristics of the mpMRI prose, such as the PRECISE score, to assess the need for a repeat biopsy according to EAU guidelines? This question remains unanswered as the specific MRI prose was not retrieved.

WHAT CARRIES WEIGHT, AND WHY
The documented prior biopsy grade (Gleason 3+4) is highly relevant as it directly impacts the clinical context for repeat biopsy. The lack of the PRECISE score is also critical because the EAU guideline explicitly links the need for repeat biopsy to MRI characteristics like the PRECISE score.

MY SUGGESTION TO THE CHAIR
Given the rising PSA trend and the high-risk PI-RADS 5 finding, and the documented prior Gleason 3+4, the evidence strongly supports proceeding with a biopsy to confirm histological progression, aligning with the leaning of the registrar.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

Given the high-risk PI-RADS 5 finding and the rising PSA trend from 5.2 to 11.0 ng/mL, coupled with the prior Gleason 3+4 pathology, a confirmatory biopsy is indicated to assess for histological progression. The evidence converged on this recommendation because the rising PSA and high-risk MRI finding strongly supported further investigation, despite the lack of a recorded surveillance protocol.

What carried weight: bx=important, age=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
